On May 22, the U.S. House of Representatives passed the Childhood Cancer Survivorship, Treatment, Access, and Research (STAR) Act (H.R. 820/S. 292), which will help improve care for the nearly 16,000 children diagnosed with cancer in the United States every year. Specifically, the bill will identify opportunities to expand research on childhood cancer and therapeutics to treat children with cancer, enhance research on the late effects of childhood cancer, and increase efforts to improve quality of life for survivors. The STAR Act passed in the Senate in March of this year. The bill will now move to President Trump for his signature.
Former president of ASCO, Michael P. Link, MD, Hon. FRCPCH, FASCO, and Co-Chair, Alliance for Childhood Cancer, said, “Despite decades of progress in cancer care, there is still limited research available on how to cure many childhood cancers and manage treatment for long-term survivors. The STAR Act will spur research into childhood cancer to give the medical community the tools they need to improve treatment outcomes for children with cancer and enhance quality of life for survivors of childhood cancer. I commend Congress for passing the most comprehensive legislation on childhood cancer that we have seen to date and urge President Trump to quickly sign the bill into law.”
ASCO has been a consistent advocate for the STAR Act and applauds Congress for their work to advance this important piece of legislation.
To stay up-to-date on the latest policy news, bookmark ASCO in Action.